Brief: Galderma Group AG - New Data Demonstrate Nemluvio®'S (Nemolizumab) Favorable Safety Profile
18/06/2025 06:03
June 18 (Reuters) - Galderma Group AG GALD.S: GALDERMA GROUP AG - NEW DATA DEMONSTRATE NEMLUVIO®'S (NEMOLIZUMAB) FAVORABLE SAFETY PROFILE Source text: ID:nBw8qTF7Ca Further company coverage: GALD.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galderma AG
See all newsBrief: Galderma Receives U.S. FDA Approval For Differin Epiduo Acne Gel Prescription-To-Otc Switch
Bayer down after 'mixed reception' at U.S Supreme Court
Europe Research Roundup: Asta Energy Solutions, Dassault Systemes, Nokia
Swiss stocks - Factors to watch on April 24
Skincare company Galderma posts 25.5% sales leap, driven by US market (updated)